For nearly half of people diagnosed with lung cancer, immunotherapy can slow the disease but not stop it. Funded through a $4 million joint investment from the Canadian Cancer Society (CCS) and the Weston Family Foundation, a new clinical trial aims to change that.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Substudy
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
A new survey study SC32S, collecting sociodemographic data from clinical trial participants, has now opened across Canada. This study will help researchers understand the feasibility of using a survey to gather information about trial participants’ backgrounds and everyday lives.
Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for New Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
Investigating Precision Medicine in the Adjuvant setting: a phase III Clinical Trial in Biliary tract cancer (SAFIR IMPACT BTC)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
The next CCTG Clinical Research Associate (CRA) Lunch and Learn training session will be on Wednesday Jun 24th, 2025, at 12 pm ET, covering the top
Reporting to the Team Leader, Ethics and Regulatory, the Ethics Research Associate will assist to conduct the ethics responsibilities of the Ethics and Regulatory (ER) office, within the Canadian Cancer Trials Group (CCTG).
Reporting and accountable to the Manager, Early Drug Development Program (EDDP), the Trial Team Leader will lead one of several teams in Trial Management Group (TMG). Teams are comprised primarily of study coordinators, research associates, and clinical trials assistants, who are involved in the coordination of clinical trials in cancer therapy, prevention and supportive care.
CRAFT - A Proposed Framework for Decentralized Clinical Trials Participation in Canada has been published in Current Oncology and is available online:
Just a reminder that Canadian Thanksgiving is fast approaching and our central office will be closed on Monday, October 11, 2021. We will reopen Tuesday, October 12, 2021 at 8;30 AM. Enjoy the holiday with your family and friends!
David Cescon MD, PhD, is a Medical Oncologist and Clinician Scientist at the Princess Margaret Cancer Centre, where his clinical practice is devoted to the care of patients with breast cancer. His research integrates laboratory and clinical studies, focused on the identification of breast cancer therapeutic vulnerabilities and determinants of drug response and resistance.
The first PALLAS Research Project Proposal Call is now open for submissions from Sep. 15th 2021 until Jan. 15th 2022. All PALLAS|MA37 investigators are eligible to submit a Research Project Proposal on available PALLAS data and samples, addressing questions that go beyond protocol defined objectives.
